Patients with advanced pancreatic cancer now have a new treatment option after the U.S. Food and Drug Administration approved Rasonque, a once-daily pill developed by Revolution Medicines.
The approval is being viewed as an important advance against a cancer that has remained extremely difficult to treat.
Rasonque is the brand name for daraxonrasib, a targeted cancer medicine designed to block proteins called RAS. These proteins normally help control cell growth, but abnormal RAS activity can act like a stuck accelerator pedal, telling cancer cells to keep growing.
Pancreatic cancer is particularly dangerous because it often causes few clear symptoms during its early stages. By the time many patients are diagnosed, the cancer has already spread beyond the pancreas and surgery is no longer possible.
The most common form is pancreatic adenocarcinoma, which begins in cells lining the ducts of the pancreas. According to the FDA, this type accounts for roughly 90% to 95% of the approximately 67,000 pancreatic cancer cases diagnosed in the United States each year.
Treatment has traditionally relied heavily on chemotherapy, particularly after the cancer has spread. Although chemotherapy can slow the disease, many tumors eventually continue growing, leaving patients with limited choices.
Rasonque offers a different strategy because it directly targets RAS, one of the main drivers of pancreatic tumor growth. For decades, scientists considered RAS extremely difficult to attack with medicines, making successful drugs against this pathway an important goal in cancer research.
The FDA approved Rasonque on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma who have already received at least one systemic treatment or who are not suitable candidates for combinations of several systemic medicines. The drug is taken by mouth at a recommended dose of 300 milligrams once daily.
The approval was based on the Phase 3 RASolute 302 clinical trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma. Participants were randomly assigned to receive either daraxonrasib or a standard chemotherapy chosen by their doctors.
The survival difference was substantial. Patients receiving daraxonrasib had a median overall survival of 13.2 months, compared with 6.7 months among those receiving standard chemotherapy.
Median survival does not mean every patient will live for exactly that amount of time. It means half the patients lived longer and half lived for a shorter period, but the comparison gives researchers a useful way to judge how treatments perform across large groups.
The drug also delayed the worsening of the cancer. Median progression-free survival was 7.2 months with daraxonrasib compared with 3.6 months with chemotherapy.
Tumors were also more likely to shrink with the new treatment. The FDA reported an overall response rate of 30% among patients receiving daraxonrasib, compared with 11% in the chemotherapy group.
These results are especially notable because the trial involved patients whose cancer had already spread and who had limited treatment options. In this setting, adding months of survival while delaying tumor growth can represent a meaningful improvement.
Rasonque is not a cure, and it can cause side effects. Common problems reported by the FDA include rash, diarrhea, mouth inflammation, nausea, tiredness, vomiting, abdominal pain, swelling, loss of appetite and bleeding.
The prescribing information also contains warnings about more serious problems, including severe skin and soft-tissue reactions, gastrointestinal perforation and inflammation in the lungs. Patients receiving the medicine will therefore need medical monitoring.
The FDA gave daraxonrasib several forms of expedited consideration, including Breakthrough Therapy and Orphan Drug designations and Priority Review. The agency said the medicine was approved about six and a half months before its expected review deadline.
The approval could have implications beyond pancreatic cancer because abnormal RAS signaling is found in many types of tumors. Researchers are studying RAS-targeted medicines in other cancers, raising the possibility that the approach may eventually help a broader group of patients.
The strongest part of the evidence is the randomized Phase 3 trial, which directly compared the new pill with standard chemotherapy and found clear improvements in survival, disease control and tumor response. That makes the approval more convincing than results based only on small early-stage studies.
However, the findings should not be interpreted as a cure for pancreatic cancer. Median survival remained a little over a year, showing that metastatic disease is still extremely serious, and longer follow-up will be important for understanding how durable the benefit is and which patients gain the most.
Overall, Rasonque represents a major step because it turns a biological target once considered extremely difficult to drug into a practical treatment. Its greatest importance may be both the extra time it can offer some patients today and what it signals about the future of RAS-targeted cancer therapy.
If you care about cancer, please read studies that low-carb diet could increase overall cancer risk, and new way to increase the longevity of cancer survivors.
For more health information, please see recent studies about how to fight cancer with these anti-cancer superfoods, and results showing daily vitamin D3 supplementation may reduce cancer death risk.
Source: U.S. Food and Drug Administration.
